Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer

BACKGROUND: CRLX101 is an investigational nanoparticle-drug conjugate with a camptothecin payload. Preclinical evidence indicated preferential uptake in tumors, and tumor xenograft models demonstrate superiority of CRLX101 over irinotecan. A pilot trial was conducted at recommended phase 2 dosing (R...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Gastrointest Oncol
Main Authors: Chao, Joseph, Lin, James, Frankel, Paul, Clark, Andrew J., Wiley, Devin T., Garmey, Edward, Fakih, Marwan, Lim, Dean, Chung, Vincent, Luevanos, Eloise, Eliasof, Scott, Davis, Mark E., Yen, Yun
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2017
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5750185/
https://ncbi.nlm.nih.gov/pubmed/29299355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.08.10
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares